Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc1:aa3 in Mycobacterium tuberculosis

[1]  S. Cole,et al.  Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis , 2018, mBio.

[2]  A. Korkegian,et al.  Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB , 2018, Journal of medicinal chemistry.

[3]  C. Vilchèze,et al.  Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. , 2018, Angewandte Chemie.

[4]  K. Read,et al.  2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure–Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization , 2018, ACS infectious diseases.

[5]  P. Hipskind,et al.  Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB , 2017, ACS infectious diseases.

[6]  Nicola Zamboni,et al.  Integration of Metabolomics and Transcriptomics Reveals a Complex Diet of Mycobacterium tuberculosis during Early Macrophage Infection , 2017, mSystems.

[7]  W. Eisenreich,et al.  Lactate oxidation facilitates growth of Mycobacterium tuberculosis in human macrophages , 2017, Scientific Reports.

[8]  M. Berney,et al.  Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection , 2017, Proceedings of the National Academy of Sciences.

[9]  M. Berney,et al.  Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions , 2017, Microbiology spectrum.

[10]  Joel S. Freundlich,et al.  A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells , 2017, mBio.

[11]  A. Steyn,et al.  Turning the respiratory flexibility of Mycobacterium tuberculosis against itself , 2016, Nature Communications.

[12]  S. Franzblau,et al.  Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo , 2016, Antimicrobial Agents and Chemotherapy.

[13]  A. Diacon,et al.  Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis , 2015, European Respiratory Journal.

[14]  Paul W Smith,et al.  Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration. , 2015, Journal of medicinal chemistry.

[15]  J. Mckinney,et al.  Targeting bacterial central metabolism for drug development. , 2014, Chemistry & biology.

[16]  Tom L. Blundell,et al.  Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.

[17]  Eduardo Gotuzzo,et al.  Multidrug-resistant tuberculosis and culture conversion with bedaquiline. , 2014, The New England journal of medicine.

[18]  Johannes Gescher,et al.  Bioengineering and Biotechnology Review Article Metabolic Engineering of Escherichia Coli for Production of Mixed-acid Fermentation End Products , 2022 .

[19]  A. Osterman,et al.  Metabolic and Bactericidal Effects of Targeted Suppression of NadD and NadE Enzymes in Mycobacteria , 2014, mBio.

[20]  I. Comas,et al.  Mapping of Genotype–Phenotype Diversity among Clinical Isolates of Mycobacterium tuberculosis by Sequence-Based Transcriptional Profiling , 2013, Genome biology and evolution.

[21]  Se Yeon Kim,et al.  Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis , 2013, Nature Medicine.

[22]  T. Dick,et al.  Characterization of Phosphofructokinase Activity in Mycobacterium tuberculosis Reveals That a Functional Glycolytic Carbon Flow Is Necessary to Limit the Accumulation of Toxic Metabolic Intermediates under Hypoxia , 2013, PloS one.

[23]  David G. Russell,et al.  Intracellular Mycobacterium tuberculosis Exploits Host-derived Fatty Acids to Limit Metabolic Stress* , 2013, The Journal of Biological Chemistry.

[24]  Joeli Marrero,et al.  Glucose Phosphorylation Is Required for Mycobacterium tuberculosis Persistence in Mice , 2013, PLoS pathogens.

[25]  C. Bertozzi,et al.  Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. , 2012, Chemistry & biology.

[26]  P. Hipskind,et al.  Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity. , 2011, ACS medicinal chemistry letters.

[27]  Sabine Ehrt,et al.  Metabolomics of Mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates. , 2010, Chemistry & biology.

[28]  K. Kuhen,et al.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy , 2010, Nature Communications.

[29]  Stefan Niemann,et al.  Mycobacterium tuberculosis wears what it eats. , 2010, Cell host & microbe.

[30]  Sabine Ehrt,et al.  Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection , 2010, Proceedings of the National Academy of Sciences.

[31]  D. van Soolingen,et al.  Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. , 2010, The Lancet. Infectious diseases.

[32]  M. Berney,et al.  Unique Flexibility in Energy Metabolism Allows Mycobacteria to Combat Starvation and Hypoxia , 2010, PloS one.

[33]  P. Wheeler,et al.  Global Effects of Inactivation of the Pyruvate Kinase Gene in the Mycobacterium tuberculosis Complex , 2009, Journal of bacteriology.

[34]  D. Crick,et al.  MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).

[35]  Stefan Niemann,et al.  High Functional Diversity in Mycobacterium tuberculosis Driven by Genetic Drift and Human Demography , 2008, PLoS biology.

[36]  Thomas Dick,et al.  The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis , 2008, Proceedings of the National Academy of Sciences.

[37]  L. Olsson,et al.  Increasing NADH oxidation reduces overflow metabolism in Saccharomyces cerevisiae , 2007, Proceedings of the National Academy of Sciences.

[38]  E. Muñoz-Elías,et al.  Carbon metabolism of intracellular bacteria , 2006, Cellular microbiology.

[39]  E. Muñoz-Elías,et al.  Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence , 2005, Nature Medicine.

[40]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[41]  D. Clark,et al.  The fermentation pathways of Escherichia coli. , 1989, FEMS microbiology reviews.

[42]  W. Segal,et al.  BIOCHEMICAL DIFFERENTIATION OF MYCOBACTERIUM TUBERCULOSIS GROWN IN VIVO AND IN VITRO , 1956, Journal of bacteriology.